Home › Funds › ADAR1 Capital Management, LLC › RYTM

ADAR1 Capital Management, LLC position in RYTM

RHYTHM PHARMACEUTICALS INC · Health Care

ADAR1 Capital Management, LLC reported holding 138,658 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$13.2M, representing 0.72% of its reported portfolio and ranking #32 among its reported holdings. ADAR1 Capital Management, LLC has disclosed RYTM holdings in 11 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)138.66K sh
Reported value held$13.20M
Portfolio Weight0.72%
First reportedQ4 2023
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How ADAR1 Capital Management, LLC's RYTM position evolved

ADAR1 Capital Management, LLC first disclosed a stake in RYTM in Q4 2023 at 1,000 shares (US$46K). The position peaked in Q1 2026 at 211,450 shares, worth US$18.4M. Across 11 filings, ADAR1 Capital Management, LLC increased the stake 8 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 138,658 shares valued at US$13.2M — an increase of 2,500 shares quarter over quarter.. Notable position changes include a 1140% increase in Q1 2024 (shares fell 5% over the following quarter), a 312% increase in Q1 2026 (shares rose 28% over the following quarter), a 36% trim in Q2 2026 (shares fell 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 1.00K $45.97K New
Q1 2024 12.40K $537.29K Add
Q2 2024 13.00K $533.78K Add
Q4 2024 30.94K $1.73M New
Q1 2025 36.89K $1.95M Add
Q2 2025 45.39K $2.87M Add
Q3 2025 49.57K $5.01M Add
Q4 2025 51.35K $5.50M Add
Q1 2026 211.45K $18.39M Add
Q2 2026 136.16K $15.12M Reduce
Q3 2026 138.66K $13.20M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RYTM and 13F data

RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RYTM

All RYTM fund holders →

FAQ

How long has ADAR1 Capital Management, LLC held RYTM?

ADAR1 Capital Management, LLC has disclosed RYTM holdings in 11 of the last 12 reported quarters, going back to Q4 2023.

What is ADAR1 Capital Management, LLC's current position in RYTM?

As of Q3 2026, ADAR1 Capital Management, LLC holds 138.66K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $13.20M, representing 0.72% of its reported portfolio and ranking #32.

Has ADAR1 Capital Management, LLC been buying or selling RYTM?

In the latest 13F filing (Q3 2026), ADAR1 Capital Management, LLC increased its position in RYTM. The position peaked in Q1 2026 at 211.45K shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.